- Our Story
- Corporate Milestone
- back
- Mar
- FDA Grants AltruBio AbGn-168H (Neihulizumab) Fast Track Designation in SR-aGVHD
- Jun
- AbGenomics changes name to AltruBio Inc.
- Jan
- Dr. Judy Chou, Joins AbGenomics as President & CEO
- Mar
- FDA Grants Abgenomics AbGn-168H (Neihulizumab) Orphan Drug Designation
- Jan
- Abgenomics demonstrated the proof of initial efficacy in a Phase-2a clinical trial study of AbGn-168H in patients with psoriatic arthritis.
- Feb
- AbGn-168H’s phase-II clinical trial targeting psoriasis completed in the United States.
- Feb
- Phase 2a clinical trial for AbGn-168H completed in the U.S.
- Nov
- Phase 1 clinical trial of AbGn-168H completed in healthy volunteers.
- Jun
- Abgenomics International Inc. (AbGUS) formed in the United States.
- Jan
- Abgenomics developed AbGn-168, a monoclonal antibody treatment for multiple immune diseases and filed a patent application with the USPTO.